[Photo provided to chinadaily.com.cn] With high regard for China's vast market potential and dynamic innovation ecosystem, Opella, Sanofi's consumer healthcare business, is expected to leverage ...

In a report released today, Raj Jilka from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The company’s shares opened today at $98.93.

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Opella, Sanofi's consumer healthcare business, is expected to leverage local platforms to drive innovation and collaborate with domestic healthcare institutions to increase its presence in the country ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13,908.88 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...

While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that having MNC stocks in your portfolio is an assurance of growth ...